EUVIMEDSkopri EUVIMED
Multizentrische StudieOpen access · CC BY 4.0

Effect of the Arg16Gly β 2 ‐Adrenergic Receptor Polymorphism on Long‐Term Mepolizumab Response and Clinical Remission in Severe Eosinophilic Asthma: A Genotype‐Stratified, Multicenter Study

Santi Nolasco iD, Evelina Fagone, Raffaele Campisi, Andrea Portacci iD, Giulia Scioscia, Corrado Pelaia, Angelantonio Maglio iD, Claudio Candia, Vitaliano Nicola Quaranta iD, Isabella Carrieri, Alessandro Saglia, Alessandro Vatrella and 8 more

Allergy · 2025

DOI: 10.1111/all.70071 ↗

At a glance

Multizentrische Studie in Allergy, 2025. Written by Santi Nolasco and 19 co-authors. Institution: Department of Clinical and Experimental Medicine, University of Catania, Catania, Italy. Major MEDLINE topics: Asthma, Receptors, Adrenergic, beta-2, Antibodies, Monoclonal, Humanized, Polymorphism, Single Nucleotide. 68 references. The full text is freely available (open access, CC BY 4.0).

AstrattSubjectsDettalji biblijografiċiCiteRelated studies

Abstract (original language)

Background β 2 ‐adrenergic signaling promotes airway smooth muscle relaxation and limits the release of pro‐inflammatory mediators by immune cells. The rs1042713 polymorphism encodes a glycine‐to‐arginine substitution (Arg16Gly) that enhances β 2 ‐receptor downregulation. We investigated the association of this polymorphism with the risk of severe eosinophilic asthma and its impact on the long‐term effectiveness of mepolizumab and clinical remission.

Methods

Genotypes from 102 patients with severe eosinophilic asthma receiving mepolizumab were compared with those from 31 individuals with mild asthma and 20 healthy controls. The severe‐asthma cohort was followed for up to 24 months, and clinical data were collected at baseline and after 3, 6, 12, and 24 months of treatment. Analyses were stratified by Arg/Arg, Arg/Gly, and Gly/Gly genotypes.

Results

Each additional Arg16 allele increased the odds of severe eosinophilic asthma by 2.61‐fold (95% CI 1.48–4.59; p = 0.0001) relative to mild asthma and by 3.61‐fold (95% CI 1.78–7.35; p < 0.0001) relative to healthy controls. Over 24 months of mepolizumab treatment, Arg/Arg patients had an increased risk of exacerbations (HR 2.3 [95% CI 1.03–5.20]; p = 0.0414) and poorer asthma control compared with Gly/Gly patients (ACT ≥ 20: 72.4% vs. 100%, p = 0.0308). Gly/Gly patients also experienced less decline in lung function. By month 24, each additional Gly16 allele increased the odds of achieving clinical remission by 2.86‐fold (95% CI 1.20–6.81; p = 0.0170), defined as no annual exacerbations, no OCS, and ACT ≥ 20, and by 3.06‐fold (95% CI 1.34–6.96; p = 0.0080) when including an FEV 1 decline ≤ 5% from baseline.

Conclusions

The Arg16 allele of the rs1042713 polymorphism increases the risk of severe eosinophilic asthma and may reduce the long‐term efficacy of mepolizumab, whereas the Gly16 allele appears to confer better outcomes and higher remission rates.

Subjects

MeSH terms (MEDLINE)

AsthmaReceptors, Adrenergic, beta-2Antibodies, Monoclonal, HumanizedPolymorphism, Single NucleotideAnti-Asthmatic AgentsEosinophiliaPolymorphism, GeneticHumansFemaleMaleAdultGenotypeMiddle AgedTreatment OutcomeAllelesRemission InductionSeverity of Illness IndexEosinophilsAmino Acid Substitution

Author keywords

Arg16Glymepolizumabremissionsevere asthmaβ2‐adrenergic receptor

Substances

mepolizumabReceptors, Adrenergic, beta-2Antibodies, Monoclonal, HumanizedAnti-Asthmatic Agents

Authors and institutions

  • Department of Clinical and Experimental Medicine, University of Catania, Catania, Italy.
  • Respiratory Medicine Unit, Policlinico "G. Rodolico-San Marco" University Hospital, Catania, Italy.
  • Institute of Respiratory Disease, Department of Translational Biomedicine and Neuroscience, University "Aldo Moro", Bari, Italy.
  • Department of Medical and Surgical Sciences, University of Foggia, Foggia, Italy.
  • Department of Health Sciences, University "Magna Graecia" of Catanzaro, Catanzaro, Italy.
  • Department of Medicine, Surgery and Dentistry, University of Salerno, Salerno, Italy.

ORCID profiles: Santi Nolasco, Andrea Portacci, Angelantonio Maglio, Vitaliano Nicola Quaranta

Cite

APA

Nolasco, S., Fagone, E., Campisi, R., Portacci, A., Scioscia, G., Pelaia, C., Maglio, A., Candia, C., Quaranta, V. N., Carrieri, I., Saglia, A., Vatrella, A., Pelaia, G., Vancheri, C., Foschino Barbaro, M. P., D'Amato, M., Carpagnano, G. E., Crimi, N., Crimi, C., & Southern Italy Network on Severe Asthma Therapy (2025). Effect of the Arg16Gly β 2 ‐Adrenergic Receptor Polymorphism on Long‐Term Mepolizumab Response and Clinical Remission in Severe Eosinophilic Asthma: A Genotype‐Stratified, Multicenter Study. Allergy. https://doi.org/10.1111/all.70071

Vancouver

Nolasco S, Fagone E, Campisi R, Portacci A, Scioscia G, Pelaia C, et al. Effect of the Arg16Gly β 2 ‐Adrenergic Receptor Polymorphism on Long‐Term Mepolizumab Response and Clinical Remission in Severe Eosinophilic Asthma: A Genotype‐Stratified, Multicenter Study. Allergy. 2025. doi:10.1111/all.70071

BibTeX
@article{Nolasco2025,
  author = {Nolasco, Santi and Fagone, Evelina and Campisi, Raffaele and Portacci, Andrea and Scioscia, Giulia and Pelaia, Corrado and Maglio, Angelantonio and Candia, Claudio and Quaranta, Vitaliano Nicola and Carrieri, Isabella and Saglia, Alessandro and Vatrella, Alessandro and Pelaia, Girolamo and Vancheri, Carlo and Foschino Barbaro, Maria Pia and D'Amato, Maria and Carpagnano, Giovanna Elisiana and Crimi, Nunzio and Crimi, Claudia and Southern Italy Network on Severe Asthma Therapy, Southern Italy Network on Severe Asthma Therapy},
  title = {Effect of the Arg16Gly β 2 ‐Adrenergic Receptor Polymorphism on Long‐Term Mepolizumab Response and Clinical Remission in Severe Eosinophilic Asthma: A Genotype‐Stratified, Multicenter Study},
  journal = {Allergy},
  year = {2025},
  doi = {10.1111/all.70071}
}
Start for free →